REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Invesco Ltd.

Invesco Ltd. reduced its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 61.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 52,128 shares of the biotechnology company’s stock after selling 84,036 shares during the period. Invesco Ltd. owned about 0.11% of REGENXBIO worth $403,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Barclays PLC grew its position in shares of REGENXBIO by 141.3% during the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after buying an additional 67,948 shares during the last quarter. GAMMA Investing LLC boosted its stake in REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,510 shares during the period. Assenagon Asset Management S.A. boosted its stake in REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after acquiring an additional 296,700 shares during the period. Hennion & Walsh Asset Management Inc. grew its holdings in shares of REGENXBIO by 8.6% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company’s stock valued at $1,273,000 after purchasing an additional 13,014 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of REGENXBIO during the 4th quarter worth approximately $1,062,000. 88.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Morgan Stanley increased their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, March 14th. HC Wainwright cut their price target on REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, March 17th. Raymond James began coverage on REGENXBIO in a report on Friday, February 7th. They issued an “outperform” rating and a $27.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a research note on Tuesday, January 21st. Finally, Leerink Partners set a $24.00 price target on REGENXBIO in a research note on Tuesday, March 18th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.63.

REGENXBIO Stock Up 5.8 %

REGENXBIO stock opened at $10.40 on Friday. The business’s 50-day simple moving average is $7.16 and its 200 day simple moving average is $8.09. The stock has a market cap of $521.22 million, a price-to-earnings ratio of -2.07 and a beta of 1.11. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $17.35.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.26. The business had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. As a group, sell-side analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.